非酒精性脂肪性肝炎新药研发：一个未被满足的临床需求

何忆宁; 施军平

doi:10.3969/j.issn.1001-5256.2021.06.001

非酒精性脂肪性肝炎新药研发：一个未被满足的临床需求

DOI: 10.3969/j.issn.1001-5256.2021.06.001

何忆宁¹,
施军平^{1, 2, ,}

1.
杭州师范大学医学部临床医学院，杭州 310018
2.
杭州师范大学附属医院肝病科，杭州 310014

基金项目:

杭州市重大科技计划项目 (20172016A03)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：何忆宁负责完成述评初稿撰写；施军平负责设计文章思路，初稿修订，审核及定稿。

详细信息

作者简介:
何忆宁(1996—)，女，主要从事非酒精性脂肪性肝病的临床研究

通信作者:
施军平，20131004@hznu.edu.cn

中图分类号: R575.5
计量
- 文章访问数: 626
- HTML全文浏览量: 304
- PDF下载量: 178
- 被引次数: 0
出版历程
- 收稿日期: 2021-05-04
- 录用日期: 2021-05-04
- 出版日期: 2021-06-20

Research and development of new drugs for nonalcoholic steatohepatitis: An unmet need in clinical practice

Yining HE¹,
Junping SHI^{1, 2
, ,}

1.
School of Clinical Medicine, Hangzhou Normal University Medical College, Hangzhou 310018, China
2.
Department of Hepatology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou 310014, China

摘要

摘要: 随着全球范围内病毒性肝炎得到有效控制，非酒精性脂肪性肝炎(NASH)在未来10年将成为肝移植的主要病因。NASH患者数量庞大，但至今尚无任何权威机构批准的治疗药物上市，这代表着一个巨大的尚未满足的临床需求。NASH复杂的发病机制、疾病异质性、诊断障碍以及治疗终点的选择等给新药研发带来了巨大挑战。
- 非酒精性脂肪性肝病 /
- 药物发现 /
- 临床试验
Abstract: With the effective control of viral hepatitis around the world, nonalcoholic steatohepatitis (NASH) will become the main cause of liver transplantation in the next ten years. There is a huge number of NASH patients, but currently no drug has been approved by authorities, which represents a large unmet need in clinical practice. The complex pathogenesis of NASH, heterogeneity of this disease, difficulties in diagnosis, and selection of treatment endpoints have brought great challenges to the research and development of new drugs.
- Non-alcoholic Fatty Liver Disease /
- Drug Discovery /
- Clinical Trial

HTML全文

参考文献(22)

[1]	YOUNOSSI Z, ANSTEE QM, MARIETTI M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(1): 11-20. DOI: 10.1038/nrgastro.2017.109.
[2]	LUDWIG J, VIGGIANO TR, MCGILL DB, et al. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease[J]. Mayo Clin Proc, 1980, 55(7): 434-438.
[3]	ALKHOURI N, LAWITZ E, NOUREDDIN M, et al. GS-0976 (Firsocostat): An investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)[J]. Expert Opin Investig Drugs, 2020, 29(2): 135-141. DOI: 10.1080/13543784.2020.1668374.
[4]	RATZIU V, SANYAL AJ, LOOMBA R, et al. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis[J]. Contemp Clin Trials, 2019, 84: 105803. DOI: 10.1016/j.cct.2019.06.017.
[5]	DAVID D, EAPEN CE. What are the current pharmacological therapies for nonalcoholic fatty liver disease?[J]. J Clin Exp Hepatol, 2021, 11(2): 232-238. DOI: 10.1016/j.jceh.2020.09.001.
[6]	ANANIA FA, DIMICK-SANTOS L, MEHTA R, et al. Nonalcoholic steatohepatitis: Current thinking from the division of hepatology and nutrition at the Food and Drug Administration[J]. Hepatology, 2021, 73(5): 2023-2027. DOI: 10.1002/hep.31687.
[7]	GOULART E, de CAIRES-JUNIOR LC, TELLES-SILVA KA, et al. 3D bioprinting of liver spheroids derived from human induced pluripotent stem cells sustain liver function and viability in vitro[J]. Biofabrication, 2019, 12(1): 015010. DOI: 10.1088/1758-5090/ab4a30.
[8]	RATZIU V, HARRISON SA, FRANCQUE S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and-δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J]. Gastroenterology, 2016, 150(5): 1147-1159. e5. DOI: 10.1053/j.gastro.2016.01.038.
[9]	SHARMA M, PREMKUMAR M, KULKARNI AV, et al. Drugs for non-alcoholic steatohepatitis (NASH): Quest for the holy grail[J]. J Clin Transl Hepatol, 2021, 9(1): 40-50. DOI: 10.14218/JCTH.2020.00055.
[10]	KIM W, KIM BG, LEE JS, et al. Randomised clinical trial: The efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2017, 45(8): 1073-1083. DOI: 10.1111/apt.13981.
[11]	ALKHOURI N. Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: Rationale for the development of resmetirom (MGL-3196)[J]. Expert Opin Investig Drugs, 2020, 29(2): 99-101. DOI: 10.1080/13543784.2020.1708899.
[12]	HARRISON SA, ROSSI SJ, PAREDES AH, et al. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis[J]. Hepatology, 2020, 71(4): 1198-1212. DOI: 10.1002/hep.30590.
[13]	GENG L, LAM K, XU A. The therapeutic potential of FGF21 in metabolic diseases: From bench to clinic[J]. Nat Rev Endocrinol, 2020, 16(11): 654-667. DOI: 10.1038/s41574-020-0386-0.
[14]	SANYAL A, CHARLES ED, NEUSCHWANDER-TETRI BA, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: A randomised, double-blind, placebo-controlled, phase 2a trial[J]. Lancet, 2019, 392(10165): 2705-2717. DOI: 10.1016/S0140-6736(18)31785-9.
[15]	SAFADI R, KONIKOFF FM, MAHAMID M, et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2014, 12(12): 2085-2091. e1. DOI: 10.1016/j.cgh.2014.04.038.
[16]	ARMSTRONG MJ, GAUNT P, AITHAL GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study[J]. Lancet, 2016, 387(10019): 679-690. DOI: 10.1016/S0140-6736(15)00803-X.
[17]	NEWSOME PN, BUCHHOLTZ K, CUSI K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J]. N Engl J Med, 2021, 384(12): 1113-1124. DOI: 10.1056/NEJMoa2028395.
[18]	SHIMIZU M, SUZUKI K, KATO K, et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease[J]. Diabetes Obes Metab, 2019, 21(2): 285-292. DOI: 10.1111/dom.13520.
[19]	JEONG SW. Nonalcoholic fatty liver disease: A drug revolution is coming[J]. Diabetes Metab J, 2020, 44(5): 640-657. DOI: 10.4093/dmj.2020.0115.
[20]	INOUE M, HAYASHI A, TAGUCHI T, et al. Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease[J]. J Diabetes Investig, 2019, 10(4): 1004-1011. DOI: 10.1111/jdi.12980.
[21]	KITAZAWA M, KATAGIRI T, SUZUKI H, et al. A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study[J]. Diabetes Obes Metab, 2021, 23(3): 811-821. DOI: 10.1111/dom.14288.
[22]	ZHAO Q, LIU J, DENG H, et al. Targeting mitochondria-located circRNA SCAR alleviates NASH via reducing mros output[J]. Cell, 2020, 183(1): 76-93. e22. DOI: 10.1016/j.cell.2020.08.009.